Dana Farber Cancer Institute DFCI (2) — Boston, Massachusetts

Dana Farber Cancer Institute DFCI (2) is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute DFCI (2) has participated in 1 clinical trials.

Therapeutic areas: Smoldering Multiple Myeloma.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute DFCI (2)?

Dana Farber Cancer Institute DFCI (2) has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute DFCI (2) conducted?

Dana Farber Cancer Institute DFCI (2) has 1 clinical trials on record. Their work covers Smoldering Multiple Myeloma.

Is Dana Farber Cancer Institute DFCI (2) accredited by Crixeo Health?

Dana Farber Cancer Institute DFCI (2) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute DFCI (2)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.